Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome

Recent reports showed that thalidomide has anti‐angiogenic activity and is effective for the treatment of refractory multiple myeloma (MM). We examined the relationship between the clinical efficacy and adverse effects of thalidomide and the plasma concentrations of this drug as well as angiogenic g...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakimoto, Tsunayuki, Hattori, Yutaka, Okamoto, Shinichiro, Sato, Norihide, Kamata, Tamihiro, Yamaguchi, Masaya, Morita, Kunihiko, Yamada, Taketo, Takayama, Nobuyuki, Uchida, Hideo, Shimada, Naoki, Tanigawara, Yusuke, Ikeda, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2002
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927128/
https://www.ncbi.nlm.nih.gov/pubmed/12359057
http://dx.doi.org/10.1111/j.1349-7006.2002.tb02480.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927128/
https://www.ncbi.nlm.nih.gov/pubmed/12359057
http://dx.doi.org/10.1111/j.1349-7006.2002.tb02480.x

Ejemplares similares